/Use Of Anti-b7h3 Antibody-drug Conjugate In Preparation Of Drug For Treating Nasopharyngeal Carcinoma And/or Lymphoepithelioma-like Carcinoma
Abstract
The present disclosure belongs to the technical field of pharmaceuticals. Specifically, the present invention relates to an anti-B7H3 antibody-drug conjugate, a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of any of the aforementioned items, and a use thereof in the preparation of a drug for treating nasopharyngeal carcinoma and/or lymphoepithelioma-like carcinoma.
Full Text
What is claimed is:
The present disclosure belongs to the technical field of pharmaceuticals. Specifically, the present invention relates to an anti-B7H3 antibody-drug conjugate, a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of any of the aforementioned items, and a use thereof in the preparation of a drug for treating nasopharyngeal carcinoma and/or lymphoepithelioma-like carcinoma.
Timeline
Filed
03/18/2026Published
07/09/2026Granted
Not AvailableIPC Codes(4)
A61K 47/68:the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 9/00:Medicinal preparations characterised by special physical form
A61P 35/00:Antineoplastic agents